Acute coronary syndrome (ACS) is a set of signs and symptoms caused by a reduction of
coronary blood flow with subsequent myocardial ischemia. ACS is associated with activation …

Background: The United States Food and Drug Administration issued a black box warning
on the mental health adverse effects of montelukast in 2020. Age-related effects on the risk …

Objective Assess the accuracy of ICD-10-CM coding of self-harm injuries and poisonings to
identify self-harm events. Materials and Methods In 7 integrated health systems, records …

Importance The evidence base for the association between montelukast and adverse
neuropsychiatric outcomes is mixed and inconclusive. Several methodological limitations …

Abstract The US Food and Drug Administration (FDA) created the Sentinel System in
response to a requirement in the FDA Amendments Act of 2007 that the agency establish a …

Suicide risk prediction models can identify individuals for targeted intervention. Discussions
of transparency, explainability, and transportability in machine learning presume complex …

Increasing environmental distress is associated with a growing asthma incidence; no
treatments are available but montelukast (MTK)—an antagonist of the cysteinyl leukotrienes …

The US Food and Drug Administration (FDA) became aware of postmarketing reports of
neuropsychiatric adverse events with Singulair (montelukast) use in 2007. Over the years …

Congress mandated the creation of a postmarket Active Risk Identification and Analysis
(ARIA) system containing data on 100 million individuals for monitoring risks associated with …

Background Recent observational studies suggest that the leukotriene receptor antagonist
montelukast may have neuropsychiatric adverse effects; however, results are conflicting …